SEER-MCache: A Prefetchable Memory Object Caching System for IoT Real-Time Data Processing

Memory object caching systems, such as Memcached and Redis, have been proved to be a simple and high-efficient middleware for improving the performance of Internet of Things (IoT) devices querying the database in cloud. However, its performance guarantee is built on the fact that the target data, queried by the IoT device, will be accessed many times and hit in the caching system. Therefore, when database system is handling the unrepeated IoT queries, it usually presents the suboptimal performance, which greatly impairs the efficiency of real-time data processing on IoT devices. To improve this issue, we propose Seer-MCache, the memory object caching system with a smart prefetching (read-ahead) function, to fill up the caching system with the desired data before the intensive IoT queries arriving. Seer-MCache includes a set of rules to launch the specific behaviors of read-head. These rules are able to be customized according to the workload characteristics and system load. We implement a prototype system in Redis (caching layer) and MySQL server (database system). Extensive experiments are conducted to verify the effectiveness of Seer-MCache, the results show that Seer-MCache can improve the performance of read-intensive workload up to 61% (39.5% in average). Meanwhile, the cost of the read-ahead behavior is moderate and controllable

Triple-L: Improving CPS Disk I/O Performance in a Virtualized NAS Environment

Network-attached storage (NAS) provides cyberphysical systems (CPS) with the scalable, efficient, and reliable backing storage, such as the mobile virtual desktop based on cloud infrastructure. Within this storage architecture, virtual machine (VM) instances running in the NAS client usually receive data from the complex physical world and then persist them in the neat cyberspace in the NAS server. In this paper, we propose Triple-L to improve VM disk I/O performance in the NAS architecture. According to the specific storage semantic, Triple-L decouples the VM image file into several subfiles at the host layer and then selectively moves them into the NAS clients. In such a way, a VM disk I/O request may be proceeded locally in the NAS client, instead of walking the external networking path repetitively between NAS server and client. We have implemented Triple-L in a Xen-based NAS system. An accessory solution for dealing with storage failure and VM live migration on Triple-L is also discussed and evaluated. The experimental result shows that our work can effectively improve the disk I/O performance of VMs. Meanwhile, it brings moderate overhead for VM live migration

Dual Semantic Fusion Network for Video Object Detection

Video object detection is a tough task due to the deteriorated quality of video sequences captured under complex environments. Currently, this area is dominated by a series of feature enhancement based methods, which distill beneficial semantic information from multiple frames and generate enhanced features through fusing the distilled information. However, the distillation and fusion operations are usually performed at either frame level or instance level with external guidance using additional information, such as optical flow and feature memory. In this work, we propose a dual semantic fusion network (abbreviated as DSFNet) to fully exploit both frame-level and instance-level semantics in a unified fusion framework without external guidance. Moreover, we introduce a geometric similarity measure into the fusion process to alleviate the influence of information distortion caused by noise. As a result, the proposed DSFNet can generate more robust features through the multi-granularity fusion and avoid being affected by the instability of external guidance. To evaluate the proposed DSFNet, we conduct extensive experiments on the ImageNet VID dataset. Notably, the proposed dual semantic fusion network achieves, to the best of our knowledge, the best performance of 84.1\% mAP among the current state-of-the-art video object detectors with ResNet-101 and 85.4\% mAP with ResNeXt-101 without using any post-processing steps.Comment: 9 pages,6 figure

In Vivo Tracking of Transplanted Mononuclear Cells Using Manganese-Enhanced Magnetic Resonance Imaging (MEMRI)

BACKGROUND: Transplantation of mononuclear cells (MNCs) has previously been tested as a method to induce therapeutic angiogenesis to treat limb ischemia in clinical trials. Non-invasive high resolution imaging is required to track the cells and evaluate clinical relevance after cell transplantation. The hypothesis that MRI can provide in vivo detection and long-term observation of MNCs labeled with manganese contrast-agent was investigated in ischemic rat legs. METHODS AND FINDINGS: The Mn-labeled MNCs were evaluated using 7-tesla high-field magnetic resonance imaging (MRI). Intramuscular transplanted Mn-labeled MNCs were visualized with MRI for at least 7 and up to 21 days after transplantation in the ischemic leg. The distribution of Mn-labeled MNCs was similar to that of ¹¹¹In-labeled MNCs measured with single-photon emission computed tomography (SPECT) and DiI-dyed MNCs with fluorescence microscopy. In addition, at 1-2 days after transplantation the volume of the site injected with intact Mn-labeled MNCs was significantly larger than that injected with dead MNCs, although the dead Mn-labeled MNCs were also found for approximately 2 weeks in the ischemic legs. The area covered by CD31-positive cells (as a marker of capillary endothelial cells) in the intact Mn-MNCs implanted site at 43 days was significantly larger than that at a site implanted with dead Mn-MNCs. CONCLUSIONS: The present Mn-enhanced MRI method enabled visualization of the transplanted area with a 150-175 µm in-plane spatial resolution and allowed the migration of labeled-MNCs to be observed for long periods in the same subject. After further optimization, MRI-based Mn-enhanced cell-tracking could be a useful technique for evaluation of cell therapy both in research and clinical applications

Sensory Communication

Contains table of contents for Section 2, an introduction and reports on twelve research projects.National Institutes of Health Grant R01 DC00117National Institutes of Health Grant R01 DC02032National Institutes of Health/National Institute of Deafness and Other Communication Disorders Grant 2 R01 DC00126National Institutes of Health Grant 2 R01 DC00270National Institutes of Health Contract N01 DC-5-2107National Institutes of Health Grant 2 R01 DC00100U.S. Navy - Office of Naval Research Grant N61339-96-K-0002U.S. Navy - Office of Naval Research Grant N61339-96-K-0003U.S. Navy - Office of Naval Research Grant N00014-97-1-0635U.S. Navy - Office of Naval Research Grant N00014-97-1-0655U.S. Navy - Office of Naval Research Subcontract 40167U.S. Navy - Office of Naval Research Grant N00014-96-1-0379U.S. Air Force - Office of Scientific Research Grant F49620-96-1-0202National Institutes of Health Grant RO1 NS33778Massachusetts General Hospital, Center for Innovative Minimally Invasive Therapy Research Fellowship Gran

PARP1 promotes nucleotide excision repair through DDB2 stabilization and recruitment of ALC1

The WD40-repeat protein DDB2 is essential for efficient recognition and subsequent removal of ultraviolet (UV)-induced DNA lesions by nucleotide excision repair (NER). However, how DDB2 promotes NER in chromatin is poorly understood. Here, we identify poly(ADP-ribose) polymerase 1 (PARP1) as a novel DDB2-associated factor. We demonstrate that DDB2 facilitated poly(ADP-ribosyl)ation of UV-damaged chromatin through the activity of PARP1, resulting in the recruitment of the chromatin-remodeling enzyme ALC1. Depletion of ALC1 rendered cells sensitive to UV and impaired repair of UV-induced DNA lesions. Additionally, DDB2 itself was targeted by poly(ADP-ribosyl)ation, resulting in increased protein stability and a prolonged chromatin retention time. Our in vitro and in vivo data support a model in which poly(ADP-ribosyl)ation of DDB2 suppresses DDB2 ubiquitylation and outline a molecular mechanism for PARP1-mediated regulation of NER through DDB2 stabilization and recruitment of the chromatin remodeler ALC1

Finishing the euchromatic sequence of the human genome

The sequence of the human genome encodes the genetic instructions for human physiology, as well as rich information about human evolution. In 2001, the International Human Genome Sequencing Consortium reported a draft sequence of the euchromatic portion of the human genome. Since then, the international collaboration has worked to convert this draft into a genome sequence with high accuracy and nearly complete coverage. Here, we report the result of this finishing process. The current genome sequence (Build 35) contains 2.85 billion nucleotides interrupted by only 341 gaps. It covers ∼99% of the euchromatic genome and is accurate to an error rate of ∼1 event per 100,000 bases. Many of the remaining euchromatic gaps are associated with segmental duplications and will require focused work with new methods. The near-complete sequence, the first for a vertebrate, greatly improves the precision of biological analyses of the human genome including studies of gene number, birth and death. Notably, the human enome seems to encode only 20,000-25,000 protein-coding genes. The genome sequence reported here should serve as a firm foundation for biomedical research in the decades ahead

Omecamtiv mecarbil in chronic heart failure with reduced ejection fraction, GALACTIC‐HF: baseline characteristics and comparison with contemporary clinical trials

Aims: The safety and efficacy of the novel selective cardiac myosin activator, omecamtiv mecarbil, in patients with heart failure with reduced ejection fraction (HFrEF) is tested in the Global Approach to Lowering Adverse Cardiac outcomes Through Improving Contractility in Heart Failure (GALACTIC‐HF) trial. Here we describe the baseline characteristics of participants in GALACTIC‐HF and how these compare with other contemporary trials. Methods and Results: Adults with established HFrEF, New York Heart Association functional class (NYHA) ≥ II, EF ≤35%, elevated natriuretic peptides and either current hospitalization for HF or history of hospitalization/ emergency department visit for HF within a year were randomized to either placebo or omecamtiv mecarbil (pharmacokinetic‐guided dosing: 25, 37.5 or 50 mg bid). 8256 patients [male (79%), non‐white (22%), mean age 65 years] were enrolled with a mean EF 27%, ischemic etiology in 54%, NYHA II 53% and III/IV 47%, and median NT‐proBNP 1971 pg/mL. HF therapies at baseline were among the most effectively employed in contemporary HF trials. GALACTIC‐HF randomized patients representative of recent HF registries and trials with substantial numbers of patients also having characteristics understudied in previous trials including more from North America (n = 1386), enrolled as inpatients (n = 2084), systolic blood pressure < 100 mmHg (n = 1127), estimated glomerular filtration rate < 30 mL/min/1.73 m2 (n = 528), and treated with sacubitril‐valsartan at baseline (n = 1594). Conclusions: GALACTIC‐HF enrolled a well‐treated, high‐risk population from both inpatient and outpatient settings, which will provide a definitive evaluation of the efficacy and safety of this novel therapy, as well as informing its potential future implementation